CMS modified NCD 101 governing thyroid testing coverage policy, effective March 7, 2026. Here's what billing teams need to know.
The Centers for Medicare & Medicaid Services updated National Coverage Determination 101, which controls Medicare coverage for thyroid function studies. This policy governs diagnostic lab testing for thyroid and pituitary hormone abnormalities — including TSH, free T4, total T4, T3 uptake, and free thyroxine index (FTI) measurements. This policy does not list specific CPT or HCPCS codes in the current version; your billing team must cross-reference the quarterly Covered Code Lists published by CMS to confirm which codes apply.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Thyroid Testing — NCD 101 |
| Policy Code | NCD 101 Medicare |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Endocrinology, Internal Medicine, Primary Care, Nephrology, Psychiatry, Cardiology, OB-GYN, Dermatology, Ophthalmology, Clinical Laboratory |
| Key Action | Audit your thyroid testing billing frequency against the two-times-per-year limit for stable patients before submitting claims after March 7, 2026 |
CMS Thyroid Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 101 is the National Coverage Determination governing Medicare coverage of thyroid function studies. CMS uses this coverage policy to define when thyroid testing is reasonable and necessary — and when it isn't.
The core of the medical necessity standard here is diagnostic purpose. Thyroid testing must serve one of six defined clinical functions to qualify for Medicare reimbursement. Know these cold.
CMS covers thyroid function testing when used to:
| # | Covered Indication |
|---|---|
| 1 | Distinguish between primary and secondary hypothyroidism |
| 2 | Confirm or rule out primary hypothyroidism |
| 3 | Monitor thyroid hormone levels in patients with goiter, thyroid nodules, or thyroid cancer |
| 4 | Monitor drug therapy in patients with primary hypothyroidism |
| 5 | Confirm or rule out primary hyperthyroidism |
| 6 | Monitor therapy in patients with hyperthyroidism |
Beyond those six, the policy extends medical necessity to a surprisingly wide range of conditions. Thyroid testing may also be covered in patients with metabolic disorders, malnutrition, hyperlipidemia, certain anemias, psychosis, non-psychotic personality disorders, unexplained depression, ophthalmologic disorders, cardiac arrhythmias, menstrual disorders, skin conditions, and myalgias.
That list is long. CMS also includes a broad catch-all: thyroid testing may be necessary for patients showing signs or symptoms affecting consciousness, the nervous system, the musculoskeletal system, skin, nutrition and metabolism, the cardiovascular system, or the gastrointestinal system.
The real issue here is frequency. For clinically stable patients, CMS covers thyroid testing up to two times per year. That's the hard line. Exceed it without documented justification and you're looking at a claim denial.
The frequency limit lifts when a patient's thyroid therapy has been changed or when new signs or symptoms of hyper- or hypothyroidism appear. In those cases, more frequent testing is reasonable and necessary — but you need the documentation to back it up. "Patient complained of fatigue" won't cut it. The record needs to show altered therapy or specific signs of thyroid dysfunction.
This policy also covers follow-up testing for patients with a personal history of malignant neoplasm of the endocrine system and patients on long-term thyroid drug therapy. If your practice sees a lot of thyroid cancer survivors or chronic hypothyroid patients on levothyroxine, this affects a significant portion of your lab billing.
NCD 101 does not mention prior authorization requirements. However, MAC-level local coverage determinations may impose additional documentation or prior auth requirements on top of this NCD. Check with your Medicare Administrative Contractor before assuming the national policy is the whole picture.
CMS Thyroid Testing Exclusions and Non-Covered Indications
NCD 101 doesn't frame exclusions as a clean list — but the frequency rule is effectively a coverage limit. Routine thyroid screening in asymptomatic patients with no documented clinical indication isn't covered under this policy. CMS covers testing that is diagnostic or therapeutic, not preventive surveillance without cause.
The policy also implies that duplicate testing — ordering TSH plus multiple complementary panels without clinical justification — is a risk area. The text specifically notes that improved test specificity has reduced the number of tests needed for most thyroid diagnoses. That language is a signal. CMS expects you to use the minimum tests necessary to reach a diagnosis or monitor therapy.
The free thyroxine index (FTI), calculated from total T4 and T3 uptake, is explicitly mentioned as useful when protein binding effects are skewing results. Ordering FTI routinely without that specific clinical context is a risk. Document why protein binding abnormalities are suspected before adding it to the panel.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Distinguish primary vs. secondary hypothyroidism | Covered | See CMS quarterly Covered Code List | Medical necessity documentation required |
| Confirm or rule out primary hypothyroidism | Covered | See CMS quarterly Covered Code List | Medical necessity documentation required |
| Monitor hormone levels — goiter, thyroid nodules, thyroid cancer | Covered | See CMS quarterly Covered Code List | Up to 2x/year for stable patients |
| Monitor drug therapy — primary hypothyroidism | Covered | See CMS quarterly Covered Code List | Up to 2x/year stable; more if therapy altered |
| Confirm or rule out primary hyperthyroidism | Covered | See CMS quarterly Covered Code List | Medical necessity documentation required |
| Monitor hyperthyroidism therapy | Covered | See CMS quarterly Covered Code List | More frequent testing covered if therapy changed |
| Metabolic disorders, malnutrition, hyperlipidemia | Covered | See CMS quarterly Covered Code List | Clinical signs must be documented |
| Certain anemias | Covered | See CMS quarterly Covered Code List | Clinical signs must be documented |
| Psychosis, non-psychotic personality disorders, unexplained depression | Covered | See CMS quarterly Covered Code List | Clinical signs must be documented |
| Ophthalmologic disorders, cardiac arrhythmias | Covered | See CMS quarterly Covered Code List | Clinical signs must be documented |
| Menstrual disorders, skin conditions, myalgias | Covered | See CMS quarterly Covered Code List | Clinical signs must be documented |
| Signs/symptoms — neurological, cardiovascular, GI, skin | Covered | See CMS quarterly Covered Code List | Broad symptom coverage; documentation required |
| Personal history of endocrine malignancy | Covered (follow-up) | See CMS quarterly Covered Code List | Follow-up testing covered |
| Long-term thyroid drug therapy | Covered (follow-up) | See CMS quarterly Covered Code List | Medical necessity for monitoring |
| FTI calculation (total T4 + T3 uptake) | Covered when protein binding effects suspected | See CMS quarterly Covered Code List | Must document clinical rationale |
| Asymptomatic screening — no clinical indication | Not Covered | N/A | No documented medical necessity |
| Frequency exceeding 2x/year — stable patient, no therapy change | Not Covered | N/A | Frequency limit applies; altered therapy or new symptoms required to exceed |
CMS Thyroid Testing Billing Guidelines and Action Items 2026
Thyroid testing billing is more complicated than it looks. The clinical breadth of this policy creates real exposure — because wide coverage criteria also mean more opportunities to get documentation wrong. Here are the steps to take before March 7, 2026.
| # | Action Item |
|---|---|
| 1 | Pull your thyroid testing claims from the last 12 months and audit frequency by patient. Flag any Medicare patient who received thyroid function tests more than twice in a year. For each flagged claim, confirm the medical record shows either a therapy change or new symptoms of hypo- or hyperthyroidism. If the documentation doesn't support exceeding the two-times-per-year limit, assess your claim denial risk and correct your processes now. |
| 2 | Download the current CMS quarterly Covered Code List for NCD 101. This policy does not enumerate specific CPT codes in its published text. The actual covered codes appear in a separate quarterly list. Make sure your charge capture and billing system are mapped to the current covered codes — not a stale list from a prior quarter. |
| 3 | Review your documentation templates for the covered indications. The policy's covered indications are broad, but "broad" doesn't mean "easy to defend." Each claim needs a diagnosis or sign/symptom that maps to one of the covered indications in the policy. Work with your clinical team to make sure the ordering documentation names the specific clinical reason — not just "thyroid panel." |
| 4 | Flag patients on long-term thyroid drug therapy and endocrine cancer survivors in your scheduling system. These patients qualify for follow-up testing under NCD 101. Make sure your billing workflow captures that distinction — it's the difference between a covered follow-up claim and an undocumented routine test. |
| 5 | Check with your Medicare Administrative Contractor for any LCD that supplements NCD 101. MACs can impose stricter local coverage criteria on top of national policy. A claim that meets NCD 101 may still fail under your MAC's local coverage determination. If you're not sure which MAC jurisdiction covers your facility, check CMS's MAC contractor list and pull any applicable LCDs before the effective date of March 7, 2026. |
| 6 | Revisit your FTI billing. When your team orders a free thyroxine index calculation — derived from total T4 and T3 uptake — the medical record needs to show why protein binding effects are clinically relevant for that patient. If your ordering templates don't prompt for that documentation, update them now. |
| 7 | If your practice bills thyroid testing across multiple specialties — psychiatry, cardiology, dermatology, OB-GYN — brief those billing teams separately. The covered indication list is clinician-specialty-specific. A psychiatrist ordering thyroid testing for unexplained depression needs different documentation than an endocrinologist monitoring a thyroid cancer patient. Same policy, different documentation paths. |
If your thyroid testing volume is high or your patient mix skews heavily toward Medicare, talk to your compliance officer before March 7, 2026. The frequency rule and the documentation requirements together create real audit exposure if your systems aren't tight.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Thyroid Testing Under NCD 101
Covered CPT Codes (When Selection Criteria Are Met)
NCD 101 as published does not list specific CPT or HCPCS codes in the policy text. CMS publishes the applicable covered codes in quarterly Covered Code Lists, updated regularly.
| Code | Type | Description |
|---|---|---|
| See CMS quarterly Covered Code List | CPT/HCPCS | Published separately from NCD 101 policy text |
To get the current covered codes, access the Covered Code Lists linked in the NCD 101 policy at the CMS website, or view the full policy record at PayerPolicy.org — NCD 101.
Additional Reference
CMS also directs billing teams to the Medicare Claims Processing Manual, Chapter 120 (Clinical Laboratory Services Based on Negotiated Rulemaking) for claims processing instructions. Cross-reference that chapter when you have questions about how to submit thyroid testing claims under Medicare billing guidelines.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.